This study identifies CLIC1 as a novel metabolic regulator that drives glycolytic reprogramming through direct interaction with PKM2 in gastric cancer. Targeting the CLIC1-PKM2 axis may provide a promising therapeutic strategy for metabolic intervention in GC and highlights a potential translational target for future clinical application.